Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240230 | 0.80 | HRH1 (0.59) | SLC6A2SLC6A3SLC6A4HRH1CARM1 | |
| SCHEMBL29856 | 0.73 | HRH1 (0.71) | SLC6A2SLC6A3SLC6A4HRH1CARM1 | |
| SCHEMBL2103220 | 0.73 | SLC6A2 (0.54) | SLC6A2SLC6A3SLC6A4HRH1FFAR4 | |
| SCHEMBL242185 | 0.73 | HRH1 (0.50) | SLC6A2SLC6A3SLC6A4HRH1CARM1 | |
| SCHEMBL15680693 | 0.72 | SLC6A2 (0.59) | SLC6A2SLC6A3SLC6A4HRH1GRIN1 | |
| Ammonia Solution, Strong SCHEMBL8078606 | 0.71 | HRH1 (0.68) | SLC6A2SLC6A3SLC6A4HRH1CARM1 | |
| SCHEMBL3244625 | 0.70 | NAAA (0.50) | SLC6A2SLC6A3SLC6A4HRH1 | |
| SCHEMBL25369234 | 0.69 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4HRH1FFAR4 | |
| SCHEMBL15574817 | 0.69 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4HRH1FFAR4 | |
| SCHEMBL15574816 | 0.69 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4HRH1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163735-B2 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| EP-1866276-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1819667-A1 | SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006102423-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006060810-A1 | SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | CTSF, CTSS, CSTB | SLC6A2 3592/4885SLC6A3 2251/4885SLC6A4 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.